AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37437694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1444
Study 37437808 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet (intervention)
Number of subjects: 20
Study 37437808 — intervention group
Group type: COMPARATOR
Intervention: Low-fat omnivorous diet (control)
Number of subjects: 20
Study 37437885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (2 mg/d)
Number of subjects: 75
Study 37437885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 37437986 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytocompounds targeting mitochondria
Number of subjects: 0
Study 37438058 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in good clinical practice and support for patient recruitment, data collection, and documentation.
Number of subjects: 0
Study 37438058 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups with researchers, semi-structured interviews with general practitioners, and questionnaires for patients.
Number of subjects: 0
Study 37438060 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated pupillometry (Neurological Pupil Index; NPi-200, Neuroptics) assessed two times per day for 7 days
Number of subjects: 213
Study 37438060 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated pupillometry parameters
Number of subjects: 213
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum of care for maternal health service utilisation
Number of subjects: 891
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion about family planning with husband
Number of subjects: 891
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Possession of electronic devices
Number of subjects: 891
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet need for family planning
Number of subjects: 891
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygamous marriage
Number of subjects: 891
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude towards family planning
Number of subjects: 891
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective norm
Number of subjects: 891
Study 37438064 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control over family planning
Number of subjects: 891
Study 37438067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (one-time male-specific counseling + facility navigation only)
Number of subjects: 0
Study 37438067 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (immediate outside-facility ART initiation + male-specific counselling + facility navigation for follow-up ART visits)
Number of subjects: 0
Study 37438067 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped intervention (increasing intensity over time)
Number of subjects: 0
Study 37438067 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 37438068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) level of 7 cmH2O during spontaneous breathing trial (SBT)
Number of subjects: 0
Study 37438071 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned sensory enhancement (PSE) training for 21 days
Number of subjects: 138
Study 37438071 — intervention group
Group type: COMPARATOR
Intervention: No patterned sensory enhancement (no-PSE) training for 21 days
Number of subjects: 138
Study 37438187 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMOs)
Number of subjects: 0
Study 37438187 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO-supplemented formula milk
Number of subjects: 0
Study 37438187 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding encouragement
Number of subjects: 0
Study 37438197 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor therapy
Number of subjects: 15
Study 37438493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prolonged-release tablet (1.9 mg melatonin)
Number of subjects: 14
Study 37438493 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release sublingual spray (1 mg melatonin)
Number of subjects: 14
Study 37438520 — intervention group
Group type: EXPERIMENTAL
Intervention: Planetary health innovation
Number of subjects: 0
Study 37438722 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach Avoidance Training (AAT) for 6 weeks
Number of subjects: 136
Study 37438722 — intervention group
Group type: COMPARATOR
Intervention: Sham training for 6 weeks
Number of subjects: 136
Study 37438734 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2627
Study 37438734 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3 ratio increase
Number of subjects: 2627
Study 37438734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2627
Study 37438741 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicle (EV) mtDNA
Number of subjects: 16
Study 37438741 — intervention group
Group type: COMPARATOR
Intervention: Whole blood (WB) mtDNA
Number of subjects: 16
Study 37438741 — intervention group
Group type: COMPARATOR
Intervention: Tumor tissues
Number of subjects: 16
Study 37438759 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing and oral-care (SOC) program; average of 6.2 days of intervention (14.8 min daily).
Number of subjects: 145
Study 37438759 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 145
Study 37438759 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing and oral-care (SOC) program; adjusted hazard ratio 2.35; 95% CI 1.38-4.01.
Number of subjects: 145
Study 37438759 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing and oral-care (SOC) program; adjusted odds ratio 0.28; 95% CI 0.12-0.65.
Number of subjects: 145
Study 37438776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge intervention comprising three SMS text message reminders with links to short educational videos and vaccine safety information.
Number of subjects: 2076
Study 37438776 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 2076
Study 37438853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1
Number of subjects: 0
Study 37438853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2
Number of subjects: 0
Study 37438853 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 37439084 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with radiotherapy (n=18)
Number of subjects: 23
Study 37439084 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy without radiotherapy (n=5)
Number of subjects: 23
Study 37439181 — intervention group
Group type: EXPERIMENTAL
Intervention: xevinapant plus chemoradiotherapy
Number of subjects: 50
Study 37439181 — intervention group
Group type: COMPARATOR
Intervention: liquid placebo plus chemoradiotherapy
Number of subjects: 50
Study 37439219 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase followed by coronary angiography and PCI (if indicated)
Number of subjects: 604
Study 37439219 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 604
Study 37439219 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase
Number of subjects: 604
Study 37439219 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase and Primary PCI
Number of subjects: 604
Study 37439259 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive In Vivo Thrombus Imaging
Number of subjects: 11
Study 37439343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenalisib 800 mg twice daily orally and romidepsin 14 mg/m2 intravenous on days 1, 8, and 15 in 28-day cycles
Number of subjects: 33
Study 37439365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic motor activation (TOMAC) for 24 weeks
Number of subjects: 103
Study 37439365 — intervention group
Group type: COMPARATOR
Intervention: Sham (control) for 24 weeks
Number of subjects: 103
Study 37439374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically diagnosed MGUS
Number of subjects: 3352
Study 37439374 — intervention group
Group type: COMPARATOR
Intervention: Screened MGUS
Number of subjects: 3352
Study 37439373 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent transfusion events
Number of subjects: 596
Study 37439373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 596
Study 37439373 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite levels (S1P, L-arginine, kynurenine, acyl-carnitines, bile acids)
Number of subjects: 596
Study 37439451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescriptions by physiotherapists for case one
Number of subjects: 47
Study 37439451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescriptions by physiotherapists for case two
Number of subjects: 47
Study 37439451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prescriptions by physiotherapists for case three
Number of subjects: 47
Study 37439451 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist characteristics (younger colleagues and those holding a Ph.D.)
Number of subjects: 47
Study 37439519 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-LB
Number of subjects: 90
Study 37439519 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous LB
Number of subjects: 90
Study 37439564 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE) research
Number of subjects: 0
Study 37439564 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient involvement in RWE studies
Number of subjects: 0
Study 37439701 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous SCB-2019 booster (full or half dose)
Number of subjects: 30
Study 37439701 — intervention group
Group type: COMPARATOR
Intervention: Homologous CoronaVac booster
Number of subjects: 30
Study 37439701 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose SCB-2019 booster
Number of subjects: 30
Study 37439701 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose SCB-2019 booster
Number of subjects: 30
Study 37439701 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 booster (full or half dose)
Number of subjects: 30
Study 37439701 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac booster
Number of subjects: 30
Study 37439701 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous SCB-2019 booster
Number of subjects: 30
Study 37439961 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine + SOC
Number of subjects: 451
Study 37439961 — intervention group
Group type: COMPARATOR
Intervention: Placebo + SOC
Number of subjects: 451
Study 37440099 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program - Neurofibromatosis (3RP-NF)
Number of subjects: 228
Study 37440099 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control (HEP-NF)
Number of subjects: 228
Study 37440156 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally based intervention
Number of subjects: 128
Study 37440205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic compliance-guided PEEP (PEEP with highest dynamic compliance plus 2 cm H2O)
Number of subjects: 40
Study 37440205 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 8 cm H2O
Number of subjects: 40
Study 37440205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic compliance-guided PEEP
Number of subjects: 40
Study 37440213 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, 0.01%, eye drops
Number of subjects: 187
Study 37440213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 37440217 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg/d for those with body weight <77 kg and/or platelet count <150 ×103/μL; 300 mg/d otherwise)
Number of subjects: 384
Study 37440217 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 384
Study 37440217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 37440232 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered emotion regulation therapy plus treatment as usual
Number of subjects: 166
Study 37440232 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 166
Study 37440230 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention (6 lay health worker-led weekly problem-solving therapy sessions)
Number of subjects: 516
Study 37440230 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (control group)
Number of subjects: 516
Study 37440230 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship Bench intervention
Number of subjects: 516
Study 37440239 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic oral vinorelbine, cyclophosphamide, and capecitabine (VEX)
Number of subjects: 140
Study 37440239 — intervention group
Group type: COMPARATOR
Intervention: Weekly intravenous paclitaxel
Number of subjects: 140
Study 37440307 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based platform for TCR selection; observational study protocol; patient samples collected, including primary tumor tissue and peripheral blood samples.
Number of subjects: 100
Study 37440425 — intervention group
Group type: EXPERIMENTAL
Intervention: New learning curve-based simulator training (individualized training time based on performance)
Number of subjects: 32
Study 37440425 — intervention group
Group type: COMPARATOR
Intervention: Reference fixed training time simulator training (1 hour)
Number of subjects: 32
Study 37440425 — intervention group
Group type: EXPERIMENTAL
Intervention: New learning curve-based simulator training
Number of subjects: 32
Study 37440465 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of home pregnancy test kits
Number of subjects: 1008
Study 37440465 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of home pregnancy test kits
Number of subjects: 1008
Study 37440465 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to purchasing home pregnancy test kits
Number of subjects: 1008
Study 37440465 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics of women with knowledge of home pregnancy test kits
Number of subjects: 1008
Study 37440465 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of women lacking support from partners
Number of subjects: 1008
Study 37440779 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Number of subjects: 0
Study 37440779 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 0
Study 37440977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Number of subjects: 81
Study 37440977 — intervention group
Group type: COMPARATOR
Intervention: Standard care exercise-based rehabilitation
Number of subjects: 81
Study 37441067 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program for 3 months and use of a pedometer watch for one year
Number of subjects: 40
Study 37441067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APA program and no pedometer watch)
Number of subjects: 40
Study 37441104 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 147
Study 37441145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment using pressure pain threshold strong response acupoints (PSA) and temperature strong response acupoints (TSA)
Number of subjects: 120
Study 37441145 — intervention group
Group type: COMPARATOR
Intervention: Intradermal acupuncture (IA) treatment using clinical common acupoint (CCA)
Number of subjects: 120
Study 37441145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment using TSA
Number of subjects: 120
Study 37441145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment using PSA
Number of subjects: 120
Study 37441145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment
Number of subjects: 120
Study 37441479 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023), an oral, first-in-class, highly potent, proximal alternative pathway inhibitor.
Number of subjects: 0
Study 37441479 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023)
Number of subjects: 0
Study 37441500 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 L of oxygen per minute in a tight-fitting simple facemask until delivery
Number of subjects: 140
Study 37441500 — intervention group
Group type: COMPARATOR
Intervention: Room air only
Number of subjects: 140
Study 37441541 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0
Study 37441541 — intervention group
Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study 37441544 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant whole brain radiotherapy (WBRT)
Number of subjects: 139
Study 37441544 — intervention group
Group type: COMPARATOR
Intervention: Observation after local treatment
Number of subjects: 139
Study 37441544 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having neurosurgery at baseline
Number of subjects: 139
Study 37441544 — intervention group
Group type: EXPERIMENTAL
Intervention: Having 2-3 brain metastases
Number of subjects: 139
Study 37441544 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 139
Study 37441546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicaderma® (Arm A)
Number of subjects: 258
Study 37441546 — intervention group
Group type: COMPARATOR
Intervention: Preventive treatment according to investigator preference (Arm B)
Number of subjects: 258
Study 37441683 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein/dairy nutrition and walking exercise intervention
Number of subjects: 0
Study 37441683 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 37442152 — intervention group
Group type: COMPARATOR
Intervention: Control group (nucleos(t)ide analogues plus placebo)
Number of subjects: 470
Study 37442152 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 dual 40 mg group
Number of subjects: 470
Study 37442152 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 dual 100 mg group
Number of subjects: 470
Study 37442152 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-3989 dual 200 mg group
Number of subjects: 470
Study 37442152 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple group (JNJ-6379 250 mg plus JNJ-3989 100 mg plus nucleos(t)ide analogues)
Number of subjects: 470
Study 37442152 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-6379 dual group
Number of subjects: 470
Study 37442271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower atmospheric pressure
Number of subjects: 9913
Study 37442271 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher humidity
Number of subjects: 9913
Study 37442271 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower temperatures
Number of subjects: 9913
Study 37442349 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (details not specified)
Number of subjects: 156
Study 37442349 — intervention group
Group type: COMPARATOR
Intervention: HSCT population
Number of subjects: 156
Study 37442349 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 156
Study 37442430 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy in 5 fractions (DL1)
Number of subjects: 8
Study 37442430 — intervention group
Group type: EXPERIMENTAL
Intervention: 42.5 Gy in 5 fractions (DL2)
Number of subjects: 8
Study 37442430 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 Gy in 5 fractions (DL3)
Number of subjects: 8
Study 37442585 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nails
Number of subjects: 1226
Study 37442585 — intervention group
Group type: COMPARATOR
Intervention: Unreamed intramedullary nails
Number of subjects: 1226
Study 37442585 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed and unreamed nails (both groups)
Number of subjects: 1226
Study 37442585 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose first reoperation was for infection
Number of subjects: 1226
Study 37442585 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients requiring multiple procedures for nonunion or bone loss
Number of subjects: 1226
Study 37442656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin extended release (XR) (5/500 mg)
Number of subjects: 80
Study 37442656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) and metformin XR (1000 mg)
Number of subjects: 80
Study 37442656 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin/metformin FDC
Number of subjects: 80
Study 37442656 — intervention group
Group type: COMPARATOR
Intervention: IC tablets (dapagliflozin [5 mg] and metformin XR [500 mg])
Number of subjects: 80
Study 37442748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab 1200 mg every 3 weeks for up to 12 months
Number of subjects: 346
Study 37442748 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 3 weeks for up to 12 months
Number of subjects: 346
Study 37442748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab 1200 mg
Number of subjects: 346
Study 37442748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 37442844 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop ventilation (INTELLiVENT-Adaptive Support Ventilation)
Number of subjects: 13
Study 37442844 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure controlled ventilation
Number of subjects: 13
Study 37442844 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop ventilation (INTELLiVENT-ASV)
Number of subjects: 13
Study 37442868 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Studio training and consultation program
Number of subjects: 13
Study 37442868 — intervention group
Group type: EXPERIMENTAL
Intervention: CHE-delivered EBIs
Number of subjects: 13
Study 37442883 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (25μg every 4 hours, maximum 5 doses)
Number of subjects: 173
Study 37442883 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion (according to hospital protocol)
Number of subjects: 173
Study 37442883 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Number of subjects: 173